AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15982464 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12652260 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. verapamil (50 mg in 500 cc saline solution at 40 ml/hr)
Number of subjects: 24
Study 12652260 — intervention group
Group type: COMPARATOR
Intervention: i.v. amiodarone (300 mg in bolus followed by 900 mg in 500 cc 5% glucosate solution, 33 ml/hr for 6 hours and subsequently 18 ml/hr)
Number of subjects: 24
Study 10480503 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 42
Study 10480503 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 42
Study 8671371 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 55
Study 8671371 — intervention group
Group type: COMPARATOR
Intervention: urinary FSH (uFSH)
Number of subjects: 55
Study 1684154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microgram/kg (DXM1)
Number of subjects: 12
Study 1684154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.2 micrograms/kg (DXM2)
Number of subjects: 12
Study 1684154 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 80 micrograms/kg (MID)
Number of subjects: 12
Study 1684154 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 31002997 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 66
Study 31002997 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 66
Study 30223190 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 258
Study 30223190 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 258
Study 26644369 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening intake of rivaroxaban (10 mg)
Number of subjects: 16
Study 24958624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated catheters
Number of subjects: 0
Study 24958624 — intervention group
Group type: COMPARATOR
Intervention: Silver alloy-coated catheters
Number of subjects: 0
Study 24958624 — intervention group
Group type: COMPARATOR
Intervention: Standard polytetrafluoroethylene (PTFE)-coated catheters
Number of subjects: 0
Study 22646064 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP tablets
Number of subjects: 100
Study 22646064 — intervention group
Group type: COMPARATOR
Intervention: PEG with sodium picosulfate
Number of subjects: 100
Study 22646064 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP tablets and PEG with sodium picosulfate
Number of subjects: 100
Study 20216569 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin protein (0.6 g protein per kg bodyweight)
Number of subjects: 8
Study 20216569 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (0.6 g protein per kg bodyweight)
Number of subjects: 8
Study 20216569 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin protein (0.6 g protein per kg bodyweight)
Number of subjects: 8
Study 20216569 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein (0.6 g protein per kg bodyweight)
Number of subjects: 8
Study 20216569 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 8
Study 19089198 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.25 W, 20 Hz, 2.84 J/cm(2)
Number of subjects: 15
Study 19089198 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.50 W, 20 Hz, 5.68 J/cm(2)
Number of subjects: 15
Study 19089198 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 0.75 W, 20 Hz, 8.52 J/cm(2)
Number of subjects: 15
Study 16003543 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-guided CVC placement
Number of subjects: 200
Study 16003543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard practice)
Number of subjects: 200
Study 11818152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted live influenza vaccine (AA-LIV)
Number of subjects: 5000
Study 11818152 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 5000
Study 10081529 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg
Number of subjects: 90
Study 10081529 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 90
Study 10081529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7743684 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg/day)
Number of subjects: 24
Study 7743684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2099751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intermittent method (trt 1)
Number of subjects: 214
Study 2099751 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose continuous method (trt 2)
Number of subjects: 214
Study 6800028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with synthetic human calcitonin (HCT 0.5 mg s.c./day, 5‐‐7 days per week) and EHDP (7.5 mg/kg, p.o.) for a mean duration of 6.1 months
Number of subjects: 23
Study 6800028 — intervention group
Group type: COMPARATOR
Intervention: HCT alone
Number of subjects: 23
Study 30870779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 94
Study 30870779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 28859603 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with load to restrain the non-paretic ankle (experimental group)
Number of subjects: 38
Study 28859603 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without load (control group)
Number of subjects: 38
Study 27480431 — intervention group
Group type: EXPERIMENTAL
Intervention: Two phase treatment (Herbst and fixed appliance)
Number of subjects: 30
Study 27480431 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance treatment only (edgewise appliance)
Number of subjects: 30
Study 25493493 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (10 sessions at specific points for smoking)
Number of subjects: 30
Study 25493493 — intervention group
Group type: COMPARATOR
Intervention: Auriculotherapy (points that have no effect on the focus of research)
Number of subjects: 30
Study 22579230 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal drainage (PD)
Number of subjects: 69
Study 22579230 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal drainage (Control)
Number of subjects: 69
Study 19711585 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 125
Study 19711585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16644621 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care (women)
Number of subjects: 874
Study 16644621 — intervention group
Group type: COMPARATOR
Intervention: Routine care (women)
Number of subjects: 874
Study 16644621 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care (men)
Number of subjects: 874
Study 16644621 — intervention group
Group type: COMPARATOR
Intervention: Routine care (men)
Number of subjects: 874
Study 12926604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin cream rinse
Number of subjects: 701
Study 12926604 — intervention group
Group type: COMPARATOR
Intervention: 0.4% d‐phenothrin shampoo
Number of subjects: 701
Study 10688391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g by intermittent bolus q12h
Number of subjects: 12
Study 10688391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 3 g by continuous infusion over 24 hours
Number of subjects: 12
Study 10688391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 4 g by continuous infusion over 24 hours
Number of subjects: 12
Study 8656324 — intervention group
Group type: EXPERIMENTAL
Intervention: High unrealistic control belief
Number of subjects: 0
Study 8656324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low realistic control belief and high unrealistic control belief
Number of subjects: 0
Study 8656324 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high controllability hassles
Number of subjects: 0
Study 8656324 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low controllability hassles
Number of subjects: 0
Study 1511641 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lateral internal sphincterotomy
Number of subjects: 112
Study 1511641 — intervention group
Group type: COMPARATOR
Intervention: Open lateral internal sphincterotomy
Number of subjects: 112
Study 6361251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (administered intravenously after cord clamping)
Number of subjects: 90
Study 6361251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31550802 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat preserving group (H group)
Number of subjects: 60
Study 31550802 — intervention group
Group type: COMPARATOR
Intervention: Non-heat preserving group (N group)
Number of subjects: 60
Study 31550802 — intervention group
Group type: COMPARATOR
Intervention: N group
Number of subjects: 60
Study 31550802 — intervention group
Group type: EXPERIMENTAL
Intervention: H group
Number of subjects: 60
Study 28590358 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 603
Study 28590358 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 603
Study 26702168 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 72
Study 26702168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23103527 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 204
Study 23103527 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 204
Study 21728433 — intervention group
Group type: EXPERIMENTAL
Intervention: PHLAME team intervention
Number of subjects: 397
Study 21728433 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 397
Study 19930436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways Triple P (PTP)
Number of subjects: 60
Study 19930436 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 60
Study 16567607 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 100 mg/d
Number of subjects: 400
Study 16567607 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 25 mg/d
Number of subjects: 400
Study 16567607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 15482037 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Diet (ED) for the first 8 weeks
Number of subjects: 315
Study 15482037 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Diet (LD) for the final 8 weeks
Number of subjects: 315
Study 15482037 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control after smoking quit date
Number of subjects: 315
Study 15482037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight management)
Number of subjects: 315
Study 11535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Neltenexine (1 tablet twice daily for 20 days)
Number of subjects: 60
Study 11535971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet twice daily for 20 days)
Number of subjects: 60
Study 9575677 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐B5 antigen
Number of subjects: 71
Study 9575677 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DR7 antigen
Number of subjects: 71
Study 9575677 — intervention group
Group type: COMPARATOR
Intervention: HLA haplotype B5‐DR5
Number of subjects: 71
Study 9575677 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA haplotypes A2‐B12, B5‐DR2, and B12‐DR4
Number of subjects: 71
Study 9575677 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA haplotypes A1‐B5 and B5‐DR5
Number of subjects: 71
Study 9575677 — intervention group
Group type: COMPARATOR
Intervention: HLA haplotype A2‐B5‐DR5
Number of subjects: 71
Study 9575677 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA haplotype A2‐B12‐DR4
Number of subjects: 71
Study 8142091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC sevoflurane alone
Number of subjects: 10
Study 8142091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 MAC sevoflurane with 0.4 MAC N2O
Number of subjects: 10
Study 8142091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MAC sevoflurane alone
Number of subjects: 10
Study 8142091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 MAC sevoflurane with 0.4 MAC N2O
Number of subjects: 10
Study 8142091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and N2O combined
Number of subjects: 10
Study 2907823 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 11
Study 2907823 — intervention group
Group type: COMPARATOR
Intervention: salazosulphapyridine (SASP)
Number of subjects: 11
Study 28623524 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 106
Study 28623524 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 106
Study 26892612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA‐A2+‐restricted peptides and Montanide, 6 doses every two weeks and a recall dose after 3 months
Number of subjects: 14
Study 26892612 — intervention group
Group type: COMPARATOR
Intervention: Vaccination for compassionate use
Number of subjects: 14
Study 25700993 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of deciduous canine
Number of subjects: 67
Study 25700993 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction
Number of subjects: 67
Study 24078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented group (1 ml of bone cement injected into the screw hole before insertion of the screw)
Number of subjects: 16
Study 24078541 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented group (no bone cement used)
Number of subjects: 16
Study 20578534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (50.1 g total fat)
Number of subjects: 19
Study 20578534 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (5.1 g total fat)
Number of subjects: 19
Study 18234086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal TNFalpha (10 microg)
Number of subjects: 0
Study 17036556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/d
Number of subjects: 0
Study 17036556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/d
Number of subjects: 0
Study 17036556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 0
Study 17036556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12716663 — intervention group
Group type: EXPERIMENTAL
Intervention: DG treatment (diacylglycerol-rich oil)
Number of subjects: 12
Study 12716663 — intervention group
Group type: COMPARATOR
Intervention: TG treatment (triacylglycerol-based control oil)
Number of subjects: 12
Study 10683712 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (100 mg)
Number of subjects: 12
Study 10683712 — intervention group
Group type: COMPARATOR
Intervention: Tilidine/naloxone (100 mg)
Number of subjects: 12
Study 9170421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 9170421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumocystosis
Number of subjects: 187
Study 9170421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus infection
Number of subjects: 187
Study 9170421 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoplasmosis
Number of subjects: 187
Study 8400752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 26
Study 8400752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan (TMP)
Number of subjects: 26
Study 8400752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) and Trimethaphan (TMP)
Number of subjects: 26
Study 2891369 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (25, 50, and 100 micrograms)
Number of subjects: 8
Study 2891369 — intervention group
Group type: COMPARATOR
Intervention: Medetomidine
Number of subjects: 8
Study 29681059 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus partial restoration (CTG + PR)
Number of subjects: 40
Study 29681059 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 40
Study 26017619 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of financial disclosure
Number of subjects: 169
Study 26017619 — intervention group
Group type: COMPARATOR
Intervention: Medium level of financial disclosure
Number of subjects: 169
Study 26017619 — intervention group
Group type: COMPARATOR
Intervention: Low level of financial disclosure
Number of subjects: 169
Study 25086065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied with autologous thrombin
Number of subjects: 54
Study 25086065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 54
Study 22670895 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 86
Study 22670895 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir
Number of subjects: 86
Study 19270472 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 169
Study 19270472 — intervention group
Group type: EXPERIMENTAL
Intervention: acamprosate
Number of subjects: 169
Study 19270472 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study 17766737 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine
Number of subjects: 0
Study 17766737 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of non-opioid analgesics (gabapentin and/or rofecoxib)
Number of subjects: 0
Study 17766737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine use during the four hours preceding 8 a.m.
Number of subjects: 0
Study 15028130 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (25000 international units at 12-hour intervals)
Number of subjects: 12
Study 15028130 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 12
Study 11798981 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (mainstay of therapy)
Number of subjects: 0
Study 11798981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative agents (under investigation)
Number of subjects: 0
Study 11798981 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9825257 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PPV
Number of subjects: 36
Study 7854794 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural somatostatin 125 micrograms every hour
Number of subjects: 40
Study 7854794 — intervention group
Group type: COMPARATOR
Intervention: Placebo: mannitol 2.5 mg
Number of subjects: 40
Study 2221484 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized wheat flour extract
Number of subjects: 30
Study 2221484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1265550 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered prostaglandin E2
Number of subjects: 100
Study 1265550 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100
Study 31055222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose EPA and DHA (3.36 g daily)
Number of subjects: 218
Study 31055222 — intervention group
Group type: COMPARATOR
Intervention: No omega-3
Number of subjects: 218
Study 25983310 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) including OptiVol and predefined management of alerts
Number of subjects: 176
Study 25983310 — intervention group
Group type: COMPARATOR
Intervention: Standard in-office visits every 3 months (control group)
Number of subjects: 176
Study 23607962 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based stress intervention (13 sessions over 1 month)
Number of subjects: 259
Study 23607962 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention during the study period)
Number of subjects: 259
Study 21664412 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 62
Study 21664412 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 62
Study 21664412 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 62
Study 19419755 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration with ADP 5 microM
Number of subjects: 120
Study 19419755 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration with ADP 20 microM
Number of subjects: 120
Study 19419755 — intervention group
Group type: COMPARATOR
Intervention: ADP 5 microM (without clopidogrel)
Number of subjects: 120
Study 19419755 — intervention group
Group type: COMPARATOR
Intervention: ADP 20 microM (without clopidogrel)
Number of subjects: 120
Study 16192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported moderate activity
Number of subjects: 225
Study 16192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported flexibility
Number of subjects: 225
Study 16192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported strength
Number of subjects: 225
Study 16192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated VO(2max) classification
Number of subjects: 225
Study 16192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Healthy People 2010 targets for moderate activity and strengthening
Number of subjects: 225
Study 12859476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol drawn up and injected through an unfiltered plastic cannula
Number of subjects: 120
Study 12859476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol drawn up through a 5-microm filter needle and injected through an unfiltered plastic cannula
Number of subjects: 120
Study 12859476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol drawn up and injected through a 5-microm filter needle
Number of subjects: 120